Mesuximide
From Infogalactic: the planetary knowledge core
| 250px | |
| Systematic (IUPAC) name | |
|---|---|
|
(RS)-1,3-dimethyl-3-phenyl-pyrrolidine-2,5-dione
|
|
| Clinical data | |
| AHFS/Drugs.com | Consumer Drug Information |
| MedlinePlus | a682028 |
| Pregnancy category |
|
| Legal status |
|
| Routes of administration |
Oral |
| Pharmacokinetic data | |
| Metabolism | Hepatic (demethylation and glucuronidation) |
| Biological half-life | 1.4–2.6 hours (mesuximide) 28–38 hours (active metabolite) |
| Excretion | Renal |
| Identifiers | |
| CAS Number | 77-41-8  |
| ATC code | N03AD03 (WHO) |
| PubChem | CID: 6476 |
| IUPHAR/BPS | 7228 |
| DrugBank | DB05246  |
| ChemSpider | 6231 |
| UNII | 0G76K8X6C0 |
| KEGG | D00404 |
| ChEMBL | CHEMBL697 |
| Chemical data | |
| Formula | C12H13NO2 |
| Molecular mass | 203.237 g/mol |
|
|
|
|
| (what is this?) (verify) |
|
Mesuximide (or methsuximide, methosuximide) is a succinimide anticonvulsant medication. It is sold as a racemate by Pfizer under the tradenames Petinutin (Switzerland)[1] and Celontin (United States).[2] The therapeutic efficacy of methosuximide is largely due to its pharmacologically active metabolite, N-desmethylmethosuximide, which has a longer half-life and attains much higher plasma levels than its parent.[3]
References
- ↑ Lua error in package.lua at line 80: module 'strict' not found.[dead link]
- ↑ Lua error in package.lua at line 80: module 'strict' not found.
- ↑ Porter RJ, Penry JK, Lacy JR, Newmark ME, Kupferberg HJ. Plasma concentrations of phensuximide, methosuximide, and their metabolites in relation to clinical efficacy. Neurology 29: 1509-1513, 1979.
<templatestyles src="Asbox/styles.css"></templatestyles>
 |
This anticonvulsant-related article is a stub. You can help Wikipedia by expanding it. |
